Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials

Key Points

• The aim is to assess the effectiveness, immunogenicity, and safety of monovalent and bivalent SARS-CoV-2 vaccines.
• Conducted two randomized, active-comparator trials.
• Evaluated monovalent DS-5670a and bivalent DS-5670a/b vaccines.
• Compared effectiveness and safety against other vaccines.
• Ensured a non-inferiority design to validate results.
• Both vaccine types show strong immunogenicity against SARS-CoV-2.
• Safety profiles appear favorable with minimal adverse effects.
• Monovalent and bivalent vaccines are effective in generating immune responses.